T1	Participants 13 30	posterior uveitis
T2	Participants 229 261	noninfectious posterior uveitis.
T3	Participants 341 446	0.59-mg FA intravitreous implant in 110 patients and the 2.1-mg FA intravitreous implant in 168 patients.
T4	Participants 1350 1396	subjects with noninfectious posterior uveitis.
